RecruitingNot ApplicableNCT07387978

A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment

A Pilot Study to Describe the Effect of Photobiomodulation in Reducing the Severity and Incidence of Oral Mucositis in Oral Cancer Patients Undergoing Radiation Treatment


Sponsor

Peter MacCallum Cancer Centre, Australia

Enrollment

30 participants

Start Date

Nov 26, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to describe the effect of photobiomodulation (PBM) on the incidence and severity of oral mucositis in post-operative oral cancer patients receiving radiotherapy +/- chemotherapy. Participants will receive PBM treatment five times a week throughout the course of their radiotherapy. The main question it aims to answer is whether photobiomodulation reduces the incidence and severity of oral mucositis.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patient has provided written informed consent using the PBM PICF
  • Age ≥ 18 years of age at Screening
  • Histological diagnosis of HNC of the oral cavity with no evidence of macroscopic or microscopic residual disease post-surgery (R0 or R1 resection) with histopathological confirmation and no gross residual lymphadenopathy in the planned PBM treatment area
  • Planned treatment with RT or chemoradiotherapy to a dose of ≥ 50 Gy Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (Appendix 1)
  • Intact oral mucosa (no visible ulceration, dehiscence, or active infection)

Exclusion Criteria7

  • Gross macroscopic and/or microscopic residual disease post-surgery (R2 resection) or gross residual lymphadenopathy in the planned PBM treatment area
  • Prior RT to the head and neck including the oral or oropharyngeal mucosa
  • Prior cytotoxic chemotherapy in the last 3 months
  • Diagnosis of photosensitive disorder (cutaneous porphyria, xeroderma pigmentosum, etc)
  • Concurrent administration of cetuximab
  • Known to be pregnant or planning to become pregnant within the trial period
  • Diagnosis of epilepsy

Interventions

DEVICEphotobiomodulation

photobiomodulation (low level laser therapy) application within and outside the oral cavity


Locations(1)

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07387978


Related Trials